Print（PDF/103KB） Mar. 30, 2022 Corporate

Notice of Establishment of Holding Company in China

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that its Board of Directors resolved at a meeting held on February 28, 2022, to establish a holding company in China as a wholly owned subsidiary.

1. Objective of the establishment
The Company decided to establish a holding company, "Sumitomo Pharma (China) Co., Ltd." in China as a wholly owned subsidiary to manage and enhance our China business.

2. Outline of the subsidiary

(1) Company name: Sumitomo Pharma (China) Co., Ltd.

(2) Location: 7th Floor, Tower A, China Overseas International Center, Lane 838, South Huangpi Road, Huangpu District, Shanghai

(3) Representative: Yoshitaka Koketsu (Chairman of the Board)

(4) Function: Manage the Company's China business as a holding company

・General management
・Shared service
・Cash pool

(5) Share capital: 30M US dollars

(6) Establishment: May 2022 (TBD)

(7) Ownership: 100% owned by the Company

(8) Fiscal year-end: December 31

(9) Number of employees: 15 (TBD)

3. Future outlook
The impact of the establishment of the holding company on the Company's consolidated financial results is minimal.